Schrodinger Inc-United States

Schrodinger insider trades reveal CEO Farid Ramy buying low, selling high, boosting confidence in its AI drug‑discovery platform and signaling a strategic shift toward long‑term growth.

Schrodinger’s insider sales are rule‑based, tax‑driven trades—no market‑move—yet the company’s IP assets and niche pharma‑software niche offer a value entry for long‑term investors.

Schrodinger Inc. insider sales in March 2026 under Rule 10b‑5‑1: liquidity‑focused, market‑neutral trades totaling $128k, yet insiders still hold 6‑8 % of shares, showing confidence and a potential growth moat in computational biology.

Insider sales spike at Schrodinger Inc. amid falling stock & negative earnings – investors weigh potential restructuring, buy‑or‑wait strategy.

Insider buying at Schrodinger signals executive confidence amid a sharp 50 % share decline, backed by promising PI3K inhibitor data and Fast‑Track FDA approval.